CAN 14
Alternative Names: CAN14Latest Information Update: 30 Oct 2025
At a glance
- Originator Cantargia
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Interleukin 1 inhibitors; Interleukin 36 inhibitors; Interleukin-33 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 16 Oct 2025 Early research in Autoimmune disorders in Sweden (Parenteral)